To overview		License Agreement

	PULSION and Carl Zeiss Conclude Exclusive License Agreement Worldwide		Downloads and Links
	A new technology for the intraoperative visualization of blood vessels is being integrated into surgical microscopes from Carl Zeiss. This technology known as IC-VIEW will considerably expand the application base of the diagnostic drug ICG-PULSION.		RTF Documents english (969 KB) Further Information Deutsche Version
	MUNICH/Germany, 01.07.2004. The companies PULSION Medical Systems AG, Munich, and Carl Zeiss, Oberkochen, have signed a license agreement for the integration of IC-VIEW technology into neurosurgical microscopes from Carl Zeiss. The agreement has been concluded on an exclusive global basis for a duration of five years. Pulsion AG, a life science enterprise specializing in medical diagnostic and therapy systems, is listed on the Prime Standard of the Frankfurt stock exchange in Germany. Carl Zeiss, the leading German company in the optical and opto-electronic industry, is a world market leader in the field of surgical visualization systems. IC-VIEW technology is based on the fluorescent properties of the diagnostic drug ICG-PULSION when irradiated with infrared light (IR) of a defined wavelength. After the intravenous injection of ICG-PULSION, irradiation with IR light makes even the smallest blood vessels or blood vessel malformations clearly visible. In addition, blood perfusion can be quantified and recorded. In this way, IC-VIEW technology allows the neurosurgeon to use a totally new method to visually check the success of the procedure during surgery. PULSION owns a large, global family of industrial property rights that protects this technology. The exclusive license agreement with Carl Zeiss covers not only neurosurgery, but also the introduction of IC-VIEW technology in other surgical disciplines. For the recently introduced OPMI Pentero surgical microscope, Carl Zeiss will present an additional option for IC-VIEW technology later this year and initially launch it on the European market. Carl Zeiss is paying license fees to PULSION, and will recommend the use of ICG-PULSION with the surgical microscopes. For PULSION, this move means a considerable expansion of the market for the ICG-PULSION drug already being successfully used in ophthalmology and liver function diagnostics. PULSION has been granted drug approval for ICG-PULSION not only in Germany, but also in the United Kingdom and expects to obtain approval in 10 further important EU countries this year. Motivated by the license agreement with Carl Zeiss, PULSION will now make FDA approval in the USA its top priority. “We are pleased to have signed this license agreement. For PULSION, it means an expansion of the ICG-PULSION application into neurosurgery and other fields on the basis of our revolutionary, minimally or non-invasive technologies. Therefore, we expect a substantial increase in world sales of ICG-PULSION. After the out-licensing of PiCCO-technology to Philips and Dräger Medical, PULSION has now also succeeded in making this essential step for achieving market penetration for IC-VIEW technology,“ says Associate Professor Ulrich Pfeiffer MD, PhD, founder and President and CEO of PULSION. “As we see it, the linking of IC-VIEW technology with our surgical microscopes represents a major advance for our customers and, above all, for the patients treated by this method. From this innovative technique that we will jointly launch on the market with PULSION, we expect a significant increase in market potential for our neurosurgical microscopes,“ is how Dr. Ludwin Monz, Executive Vice President and General Manager of the Medical Systems Group of Carl Zeiss, describes future prospects. Markus Wiederspahn Carl Zeiss SMT AG Marketing Phone: +49 7364 20-2194 Fax: +49 7364 20-9206 E-Mail: wiederspahn@smt.zeiss.com Number: 073/04 OP Number of Words: 542 Number of Characters: 3772

Go To Top To overview